The ozempic segment is expected to hold the largest Glp-1 analogues market share due to its high preference for diabetics globally
2.2 Statistical analysis We conducted a power analysis for the study, considering a minimally relevant effect size () of a 5 kg weight change, a two-tailed test, a minimum desired power of 0.9, and = 0.05
Lixisenatide and PD Lixisenatide is another GLP-1 RA indicated for the treatment of T2DM
Experiment with different texturessome patients prefer softer foods, whilst others find crunchy vegetables more satisfying
Compared with T2DM mice, LEO treated group showed a significant increase in the Simpson index, indicating LEO could elevate the copiousness and diversity of the intestinal gut microbiome
This dual action helps stabilize blood sugar, reducing the likelihood of cravings for sugary or high-carbohydrate foods that can hinder weight loss efforts